Literature DB >> 17932167

Let cost effectiveness models be open to scrutiny.

Chris Poole, Samir Agrawal, Craig J Currie.   

Abstract

Mesh：

Year:  2007        PMID： 17932167      PMCID： PMC2018758          DOI： 10.1136/bmj.39360.379664.BE

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.

Authors:  Cathie L M Sudlow; Carl E Counsell
Journal:  BMJ       Date:  2003-02-15

2.  Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting.

Authors: 
Journal:  Diabetes Care       Date:  2007-06       Impact factor: 19.112

3.  Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

Authors:  Jim Chilcott; Chris McCabe; Paul Tappenden; Anthony O'Hagan; Nicola J Cooper; Keith Abrams; Karl Claxton; David H Miller
Journal:  BMJ       Date:  2003-03-08
  3 in total
  3 in total

1.  Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.

Authors:  Eric Q Wu; Zheng-Yi Zhou; Jipan Xie; Cinzia Metallo; Praveen Thokala
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

2.  Benefits, Challenges and Potential Strategies of Open Source Health Economic Models.

Authors:  William C N Dunlop; Nicola Mason; James Kenworthy; Ron L Akehurst
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

3.  Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis.

Authors:  Ferrán Catalá-López; Lisa Caulley; Manuel Ridao; Brian Hutton; Don Husereau; Michael F Drummond; Adolfo Alonso-Arroyo; Manuel Pardo-Fernández; Enrique Bernal-Delgado; Ricard Meneu; Rafael Tabarés-Seisdedos; José Ramón Repullo; David Moher
Journal:  BMJ Open       Date:  2020-02-13       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.